Urolog. pro Praxi, 2006; 1: 12-14

NEW TRENDS IN THE CONSERVATIVE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA

MUDr. Martin Lukeš1, MUDr. Miroslav Záleský2, doc. MUDr. Michael Urban1
1 Urologická klinika 3. LF UK a FN KV v Praze
2 Urologické oddělení, Fakultní Thomayerova nemocnice Praha

Benign prostatic hyperplasia (BPH) is the most common benign tumour in older men. Clinical manifestation of this disease demonstrated by lower urinary tract symptoms deteriorates quality of life of patients. Authors summarize current possibilities of modern non-surgical therapy of benign prostatic hyperplasia, watchful waiting and pharmacological therapy.

Keywords: Key words: benign prostatic hyperplasia, watchful waiting, pharmacological therapy.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukeš M, Záleský M, Urban M. NEW TRENDS IN THE CONSERVATIVE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA. Urol. praxi. 2006;7(1):12-14.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21(2): 167-178. Go to original source... Go to PubMed...
    2. Andriole GL, Guess HA, Epstein JL, et al. Treatment with finasteride preserves usefulness of prostate specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998; 52: 195-201. Go to original source... Go to PubMed...
    3. Andriole GL, Kirby R. Safety and tolerability of the Dual 5 alpha-Reductase Inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44: 82-88. Go to original source... Go to PubMed...
    4. Barry JJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479. Go to original source... Go to PubMed...
    5. Bosch JLHR, Hop WCJ, Kirkels WJ, Schröder FH. The international prostate symptom score in a community-based sample of men between fifty-five and seventy-four years of age. Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J urol 1995; 75: 622-630. Go to original source... Go to PubMed...
    6. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts the outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405. Go to original source... Go to PubMed...
    7. Bruskewitz R, Girman CJ, Fowler J et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999; 4: 670-678. Go to original source... Go to PubMed...
    8. De la Rosette J, Madersbacher S, Alivizatos G. Guidelines on benign prostatic hyperplasia. In: Urological guidelines EAU March 2004 Edition; 7: 53.
    9. Djavan B, Marberger M. Meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36(1): 1-13. Go to original source... Go to PubMed...
    10. Foley SJ, Soloman LZ, Wedderburn AW, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol. 2000; 163: 496-498. Go to original source... Go to PubMed...
    11. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989; (Suppl 2): 33-50. Go to original source... Go to PubMed...
    12. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 2000; 56: 3-6. Go to original source... Go to PubMed...
    13. Kirby RS et al. Textbook of Benign Prostatic Hyperplasia. Oxford: Isis Medical Media 1996.
    14. Matsumoto AM, Tenover L, McClung M, et al. PLESS Study Group. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 2002; 167: 2105-2108. Go to original source... Go to PubMed...
    15. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5alfa-reductase, supresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endo Metab 1992; 74: 505-550. Go to original source...
    16. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-563. Go to original source... Go to PubMed...
    17. McConnell JD. The long term effects of medical therapy on the progression of BPH: Results from the MTOPS trial. J Urol 2002; 167 (4): 265. Go to PubMed...
    18. Roehrborn CG, Bruskewitz R, Nickel GC, et al. Urinary retention in patients with BHP treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. Eur Urol 2000; 37: 528-536. Go to original source... Go to PubMed...
    19. Silver RI, Wiley EL, Thigpen AE, et al. Cell type specific expression of steroid 5alfa-reductase 2. J Urol 1994; 152: 438-442. Go to original source... Go to PubMed...
    20. Wessells H, Roy J, Bannow J, et al. PLESS Study Group. Incidence and severity of sexual adverse experiences in finasterides and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61: 579-584. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.